Mylan Rolls Out Semglee Insulin In Australia
Immediately upon reimbursement listing, Mylan has launched in Australia the insulin glargine biosimilar that it co-developed with India’s Biocon.
You may also be interested in...
Mylan and Biocon have launched their Semglee version of insulin glargine in the US, revealing pricing details for the Lantus rival. At the same time, the firms have offered an update on their attempts to have Semglee classified as a biosimilar as they seek an interchangeability designation.
Mylan and Biocon have launched their Fulphila biosimilar version of pegfilgrastim in Australia, marking the pair’s third local biosimilar launch under their partnership.
A US district court has ruled in favor of Mylan in a dispute with Sanofi over a Lantus SoloStar device patent, with the patent protecting the insulin glargine injector pen found to be invalid and not infringed. Mylan, along with partner Biocon, expects to launch its Semglee version mid-year, following FDA approval.